EP0180276A1 — Dioxaphosphorinanes, their preparation and use for resolving optically active compounds
Assigned to Koninklijke DSM NV · Expires 1986-05-07 · 40y expired
What this patent protects
New dioxcaphosphorinanes having the formula: in which: M denotes a hydrogen atom or a metal or ammonium ion, R1 and R2 denote a hydrogen atom, a halogen atom, an alkyl group having 1 up to 4 carbon atoms, an alkoxy group having 1 up to 4 carbon atoms, a nitro group…
USPTO Abstract
New dioxcaphosphorinanes having the formula: in which: M denotes a hydrogen atom or a metal or ammonium ion, R1 and R2 denote a hydrogen atom, a halogen atom, an alkyl group having 1 up to 4 carbon atoms, an alkoxy group having 1 up to 4 carbon atoms, a nitro group or together denote a methylene dioxy group and R3 and R4 denote hydrogen atom, a halogen atom, an alkyl group having 1 up to 4 carbon atoms or together denote a cyclohexyl group, one at most of the groups R3 and R4 denoting a hydrogen atom. A process for the preparation of these dioxaphosphorinanes from a substituted 1-phenyl-1,3-dihydroxypropane by reacting this product with phosphoryl choride, the resolution of the dioxaphosphorinanes in optical isomers by reacting with an optically active amino compound and the resolution of racemates of a plurality of amino compounds, such as hydroxyphenylglycine and phenylalanine, in optically active isomers by reacting with said dioxaphosphorinanes are described.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.